{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086410","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.270044+00:00","generated_at":"2026-06-08T03:50:42.805048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BiomX reports Q3 net loss $7.9M, cash $23.4M, BX004 Part 2 data expected this month","bullets":["Net loss for Q3 2023 was $7.9 million, compared to $6.8 million for Q3 2022.","Cash and equivalents stood at $23.4M as of Sep 30, 2023, down from $34.3M at Dec 31, 2022.","Part 2 data from Phase 1b/2a trial of BX004 for cystic fibrosis expected later in November 2023.","In August 2023, BX004 received FDA Fast Track designation for chronic respiratory infections in CF patients.","Board appointed Edward L. Williams, former executive at Ascendis, Novo Nordisk, and Novartis, in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086410","json":"https://secwatch.observer/filing/0001213900-23-086410.json","markdown":"https://secwatch.observer/filing/0001213900-23-086410.md","text":"https://secwatch.observer/filing/0001213900-23-086410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/0001213900-23-086410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/ea188340-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:50:42.805048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92d091ebbd86ac7b6b357f1168f29dcaabe5e372","claim":"BiomX Inc. reported financial results for for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, BiomX Inc. (the \"Company\") issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023086410/0001213900-23-086410-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}